Bulls holding strong on VITROMXSTO:VITR
Despite several attemps from the bears to reach the 160 level, the bulls are stronly in control.
It got cheap in the process. Probably a good opportunity.
Risk 15%
Next report date
Report period
Q2 2024
EPS estimate
0.09EUR
Revenue estimate
78.23 MEUR
−2.45EUR
−344.37 MEUR
314.05 MEUR
69.04 M
About VITROLIFE AB
Sector
Industry
CEO
Bronwyn Brophy
Website
Headquarters
Gothenburg
Employees (FY)
1.12 K
Founded
1989
ISIN
SE0011205202
FIGI
BBG000DPCYC8
Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. Its products and services include oocyte retrieval needles, sperm processing, IVF media and oil, micromanipulation pipettes, labware, benchtop incubators, time-lapse systems, preimplantation genetic testing, cryopreservation, laser and imaging systems, and lab quality control systems. The firm operates through the following geographical segments: Europe, Middle East, and Africa (EMEA); North and South America; Japan and Pacific; and Asia. The company was founded in 1994 and is headquartered in Gothenburg, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange VITROLIFE AB SK 0,2 stocks are traded under the ticker VTFN.
VITROLIFE AB SK 0,2 is going to release the next earnings report on Jul 17, 2024. Keep track of upcoming events with our Earnings Calendar.
VTFN earnings for the last quarter are −2.76 EUR per share, whereas the estimation was 0.08 EUR resulting in a −3.55 K% surprise. The estimated earnings for the next quarter are 0.08 EUR per share. See more details about VITROLIFE AB SK 0,2 earnings.
VITROLIFE AB SK 0,2 revenue for the last quarter amounts to 80.84 M EUR despite the estimated figure of 80.84 M EUR. In the next quarter revenue is expected to reach 75.72 M EUR.
Yes, you can track VITROLIFE AB SK 0,2 financials in yearly and quarterly reports right on TradingView.
VTFN net income for the last quarter is 9.95 M EUR, while the quarter before that showed −373.70 M EUR of net income which accounts for 102.66% change. Track more VITROLIFE AB SK 0,2 financial stats to get the full picture.
Yes, VTFN dividends are paid annually. The last dividend per share was 0.09 EUR. As of today, Dividend Yield (TTM)% is 0.52%. Tracking VITROLIFE AB SK 0,2 dividends might help you take more informed decisions.
Like other stocks, VTFN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VITROLIFE AB SK 0,2 stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 29, 2024, the company has 1.12 K employees. See our rating of the largest employees — is VITROLIFE AB SK 0,2 on this list?
We've gathered analysts' opinions on VITROLIFE AB SK 0,2 future price: according to them, VTFN price has a max estimate of 22.69 EUR and a min estimate of 17.98 EUR. Read a more detailed VITROLIFE AB SK 0,2 forecast: see what analysts think of VITROLIFE AB SK 0,2 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VITROLIFE AB SK 0,2 EBITDA is 100.67 M EUR, and current EBITDA margin is 32.97%. See more stats in VITROLIFE AB SK 0,2 financial statements.